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Introduction
Gastrointestinal (GI) cancer, particularly colorec-
tal, gastric, esophageal and pancreatic malignan-
cies, are among the most common cancer types 
worldwide [Ferlay et al. 2014]. Moreover, the high 
rate of metastatic disease accounts for the overall 
high mortality rates. Due to anatomical location 
and venous drainage the liver is the predominant 
organ for metastatic manifestation of tumors aris-
ing from the GI tract. Thus, impaired liver func-
tion and finally liver failure are common among GI 
cancer patients. On the other hand, the approved 
treatment combinations are based on clinical trials 
of selected patients with good liver function and 
normal values of bilirubin [<1.5 times upper limit 
of normal (ULN)] and transaminases.
Metastatic liver involvement may result in liver 
dysfunction, indicated by increased bilirubin 
(hyperbilirubinemia), increased level of choles-
tatic parameters (gamma-glutamyl transferase and 
alkaline phosphatase) and transaminases as well as 
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Abstract
Background: Treatment of patients with severe liver dysfunction including hyperbilirubinemia 
secondary to liver metastases of gastrointestinal (GI) cancer is challenging. Regimen of 
oxaliplatin and fluoropyrimidine (FP)/folinic acid (FA) ± a monoclonal antibody (moAb), 
represents a feasible option considering the pharmacokinetics. Clinical data on the respective 
dosage and tolerability are limited and no recommendations are available.
Methods: Consecutive patients with severe hyperbilirubinemia [>2 × upper limit of the 
normal range (ULN) and >2.4 mg/dl] due to liver metastases of GI cancer without options for 
drainage receiving oxaliplatin, FP/FA ± moAb were analyzed. To collect further data a review 
of the literature was performed.
Results: A total of 12 patients were identified between 2011 and 2015. At treatment start, 
median bilirubin level was 6.1 mg/dl (>5 × ULN, range 2.7–13.6). The majority of patients 
(n = 11) received dose-reduced regimen with oxaliplatin (60–76%) and FP/FA (0–77%), 
rapidly escalating to full dose regimen. During treatment, bilirubin levels dropped more 
than 50% within 8 weeks or normalized within 12 weeks in 6 patients (responders). Median 
overall survival was 5.75 months (range 1.0–16.0 months) but was significantly prolonged in 
responders compared to nonresponders [9.7 and 3.0 months, p = 0.026 (two-sided test); 95% 
confidence interval (CI): 1.10–10.22]. In addition, case reports or series comprising a further 26 
patients could be identified. Based on the obtained data a treatment algorithm was developed.
Conclusion: Treatment with oxaliplatin, FP/FA ± moAb is feasible and may derive relevant 
benefits in patients with severe liver dysfunction caused by GI cancer liver metastases without 
further options of drainage.
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impaired liver synthesis (e.g. low albumin). 
Pretreatment evaluation of liver dysfunction is 
important to ensure treatment tolerability and 
thus efficacy. Within the above-mentioned labora-
tory values, bilirubin is often used for a rough esti-
mate of liver function and the consecutive 
treatment selection. Hyperbilirubinemia may have 
different reasons, in the case of severe liver involve-
ment without options for biliary drainage, active 
and tolerable systemic treatment may reduce 
tumor burden and alleviate symptoms. By con-
trast, hyperbilirubinemia due to extrahepatic chol-
estasis may be managed by drainage and bilirubin 
will recover over time. Thus, tolerability will be 
the central concern of treatment administration.
Several systemic agents are available for GI can-
cer (e.g. irinotecan, fluoropyrimidine, taxanes 
and platin compounds), which differ highly in 
terms of pharmacokinetics, particularly regarding 
hepatic metabolism. For example, bioactivation 
of irinotecan and detoxification of its metabolite 
SN-38 occurs predominantly in the liver and thus 
drug clearance is diminished in patients with 
hepatic dysfunction [Rivory and Robert, 1995; 
Gagne et al. 2002]. The tolerability of irinotecan 
in patients with hepatic dysfunction (bilirubin 
greater than 2 mg/dl) has not been assessed suffi-
ciently and no recommendations for dosing can 
be made. Fluoropyrimidines (FP) are eliminated 
primarily by hepatic metabolism, with less than 
5% of the drug excreted in the urine in normal 
individuals [Schalhorn and Kuhl, 1992; Schilsky, 
1998]. Capecitabine, a prodrug of 5-Fluororuracil 
(5-FU) is activated through three enzymatic reac-
tions. Although high activities of drug metaboliz-
ing enzymes are expressed in human liver, the 
involvement of the liver in capecitabine metabo-
lism is not fully understood and the use in patients 
with hepatic failure is controversially discussed 
[Twelves et  al. 1999; Saif and Tejani, 2007]. 
Available reports showed no clinically significant 
influence on the pharmacokinetics of capecit-
abine and its metabolites by modestly impaired 
hepatic function [Twelves et  al. 1999; Saif and 
Tejani, 2007]. Taxanes (docetaxel or paclitaxel) 
are predominantly eliminated by hepatobiliary 
extraction and are thus already contraindicated in 
case of modest liver dysfunction [Bruno et  al. 
2001; Hooker et  al. 2008; Minami et  al. 2009; 
Eckmann et al. 2014]. In contrast to irinotecan, 
fluoropyrimidines and taxanes, oxaliplatin is rap-
idly cleared from plasma by binding to tissue and 
renal elimination [Graham et al. 2000; Jerremalm 
et al. 2009]. Urinary excretion (53.8 ± 9.1%) is 
the major route of platinum elimination. In addi-
tion, oxaliplatin undergoes rapid and extensive 
nonenzymatic biotransformation [Graham et  al. 
2000].The favorable pharmacokinetic profile 
makes oxaliplatin a systemic agent of particular 
interest in patients with liver dysfunction.
Clinical data on the use of systemic chemotherapy in 
hepatic dysfunction are limited, particularly for cur-
rent standard combination regimen including mon-
oclonal antibodies (moAbs). Available data mainly 
confer to small case series on the use of oxaliplatin in 
combination with infusional 5-FU or capecitabine 
for either metastatic colorectal (mCRC) or gastric 
cancer or single agent cetuximab [Fakih, 2004; 
Hwang et al. 2006; Walia et al. 2008; Mizota et al. 
2011; Elsoueidi et al. 2014; Tural et al. 2014].
In order to establish a dose recommendation for 
administration of current combination regimen 
including moAbs, bi-institutional case series and 
a literature review was performed.
Materials and methods
Consecutive patients with severe liver dysfunc-
tion and hyperbilirubinemia (>2 × ULN, >2.4 
mg/dl) due to liver metastases of GI malignancies 
from two German institutions treated between 
August 2011 and April 2015 were analyzed for 
outcome, adverse events, liver function tests and 
blood count. Patients with hyperbilirubinemia 
were screened for options of internal or external 
biliary drainage by different imaging modalities 
(computed tomography, magnet resonance 
tomography or ultrasound) and discussed within 
the multidisciplinary tumor board. Only patients 
with hyperbilirubinemia caused by diffuse meta-
static liver involvement after exclusion of further 
options for biliary drainage and no extrahepatic 
cholestasis were included in the analysis. Patients 
with known nonmalignant liver diseases like hep-
atitis, fibrosis or cirrhosis were excluded. The 
treatment had to contain any FP, folinic acid 
(FA) and oxaliplatin with or without moAbs.
Patients were stratified into two groups according 
to the respective decrease in bilirubin levels fol-
lowing treatment.
Responders were defined as those with a reduc-
tion of bilirubin levels of at least 50% within 
the first 4–8 weeks or normalization up to week 
12. The remaining patients were defined as 
nonresponders.
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For the literature review relevant data from pub-
lished trials, reports and abstracts presented at 
selected oncology association meetings [American 
Society of Clinical Oncology (ASCO), European 
Society for Medical Oncology (ESMO), European 
CanCer Organisation (ECCO)] and Medline/
Pubmed until July 2015 were reviewed.
Results
Detailed results of the literature review are shown 
in Table 1. Overall 11 case reports or case series 
about hyperbilirubinemia in patients (a total of 26 
patients) with GI cancers (25 with mCRC) and 
one with gastric cancer were found.
Elevated bilirubin levels due to liver metastases 
ranged from 2.6 mg/dl to 29.8 mg/dl before treat-
ment start. The majority of patients (n = 18) had 
not undergone any prior systemic treatment. 
After treatment start, bilirubin decreased in 16 of 
25 patients (missing n = 1). Only one patient 
with mCRC received an irinotecan based chemo-
therapy regimen (FOLFIRI), in combination 
with bevacizumab as first line treatment [Yeh 
et  al. 2014]. In this patient initial bilirubin was 
5.94 mg/dl and dropped to 0.78 mg/dl after 4 
cycles; overall survival (OS) was 9 months.
Shitara and colleagues reported on seven heavily 
pretreated patients with mCRC treated with 
cetuximab alone [Shitara et  al. 2010]. In these 
patients median bilirubin at treatment start was 
7.4 mg/dl. In five of seven patients bilirubin 
dropped less than 50% of the initial value. 
Treatment with cetuximab alone was feasible, 
however outcome was poor with a median OS of 
2.4 months.
Eighteen patients were treated with oxaliplatin-
based chemotherapy regimens (with any FP; with 
or without moAb; no moAb: n = 11, bevaci-
zumab: n = 3, cetuximab: n = 1, panitumumab: 
n = 1) [Fakih, 2004; Hwang et al. 2006; Walia 
et  al. 2008; Grenader et  al. 2009; Mizota et  al. 
2011; Terasawa et al. 2013; Elsoueidi et al. 2014; 
Tural et al. 2014; Kasi et al. 2015] with bilirubin 
ranged from 3.2–29.8 mg/dl at treatment start, 
that dropped in 14 patients by more than 50%. 
OS ranged from 1.5 months to 18 months. All 
treatment regimens were feasible without any 
severe toxicity (grade ⩾3).
In our case series, 12 patients were identified 
(Table 2): 9 male and 3 female, with a median 
age of 59 (range 46–74) years. Tumor types were 
colorectal (n = 6), biliary tract (n = 5) and gas-
troesophageal cancer (n = 1). In addition to dif-
fuse liver metastases, they also presented lung 
(n = 3), bone (n = 3) and lymph node (n = 6) 
metastases. Before the malignant liver involve-
ment none of the patients had any preexisting 
liver diseases. In all patients, drainage by stent 
placement or percutaneous transhepatic biliary 
drainage was evaluated and if feasible done before 
systemic treatment with 5-FU/FA, oxaliplatin ± 
moAb. Thus, hyperbilirubinemia was solely 
caused by diffuse malignant liver infiltration with 
all other potential causes ruled out. Prior systemic 
chemotherapy, either in the adjuvant or meta-
static setting, was administered in eight patients. 
In four patients 5-FU/FA, oxaliplatin ± moAb 
was the firstline treatment.
Liver dysfunction was documented prior to sys-
temic treatment (but after maximal drainage) by 
a median bilirubin level of 6.1 mg/dl (range 2.7–
13.6 mg/dl), median alkaline phosphatase (AP) 
level of 571.0 U/l (range 192–938  U/l), median 
gamma-glutamyl transpeptidase (gGT) 422.75 U/l 
(range 165–1446 U/l), median glutamic-pyruvic 
transaminase (GPT) level of 76.0 U/l (range 29–
283 U/l) and median level of glutamic-oxaloacetic 
transaminase (GOT) 140.0 U/l (range 82–441 U/l). 
Liver synthesis function was relevantly impaired, 
shown by low levels of albumin (median level of 
31 g/l, range 20–38) and elevated international 
normalized ratio (INR) of prothrombin time 
(median 1.3, range 0.92–1.84).
Oxaliplatin was administered with infusional 5-FU/
FA once a week (n = 5) or every two weeks (n = 7) 
or with capecitabine every three weeks (n = 1). 
Chemotherapy was combined with bevacizumab 
(n = 4), trastuzumab (n = 1) or cetuximab (n = 1).
Upfront dose reductions were applied in five 
patients for oxaliplatin (60–76% of full dose) and 
in 10 patients for 5-FU (0–77% of full dose). In 
one patient, treatment was started with fully 
dosed chemotherapy.
Only in one patient, a dose escalation of oxalipl-
atin to full standard doses was done. However, 
the weekly FUFOX regimen was changed to 
every two weeks FOLFOX in two patients. 
Escalation of 5-FU/FA to full standard doses was 
done within median 3.8 weeks, respectively. 
Individual dosing strategies are displayed in 
Table 2.
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Table 1. Results of literature review.
n Tumor Metastases Prior 
treatment
Treatment Bilirubin (mg/dl) OS in 
months
 Before 
treatment
During/ 
after 
treatment
Yeh et al. 
[2014]
1 colorectal liver no 4 cycles red FOLFIRI plus 
bevacizumab 5 mg/kg
8 cycles FOLFIRI plus bevacizumab 
5 mg/kg
5.94 after 4 
cycles: 0.78
9
Shitara et al. 
[2009, 2010]
7 colorectal liver, lung, 
lymph node, 
peritoneum
yes cetuximab mono 6.5 (mean 
level)
nk
(no drop in 5 
of 7 pts)
2.5 (mean 
OS)
Fakih [Fakih, 
2004]
3 colorectal liver no 2 cycles red FOLFOX (Ox 60 mg/qm, 
LV 200 mg/qm, bolus 5-FU 300 mg/
qm, 5-FU 46 h infusion 1800 mg/qm)
12 cycles FOLFOX
3.5 1.2 7
colorectal liver no 1 cycle red FOLFOX (Ox 65 mg/qm, 
LV 400 mg/qm, 5-FU 46 h infusion 
2000 mg/qm)
7 cycles FOLFOX
5.9 1.8 4
sigmoid liver no 1 cycle red FOLFOX (Ox 85 mg/qm, 
LV 400 mg/qm, 5-FU 46 h infusion 
2000 mg/qm)
10 cycles FOLFOX
4.2 1.3 ongoing
Hwang et al. 
[2006]
1 gastric liver yes 5 cycles Ox 130 mg/qm capecitabine 
1000 mg/qm
10.9 2.1 ongoing
Walia et al. 
[2008]
6 colorectal liver no FOLFOX (dose unknown) 16.2 0.6 9.4
colorectal liver no FOLFOX (dose unknown) + 
bevacizumab
27.7 2.5 2
colorectal liver no XELOX 6.2 no drop 0.8
colorectal liver no FOLFOX (dose unknown) 3.5 no drop 1.5
colorectal liver no FOLFOX (dose unknown) 12.5 3.0 nk
colorectal liver no FOLFOX (dose unknown) 6.5 5.7 2.4
colorectal liver no unknown 3.2 nk nk
Elsoueidi 
et al. [2014]
1 colorectal liver no 21 cycles red FOLFOX (Ox 75 mg/
qm, 5-FU Bolus 200 mg/qm, 5-FU 46 
h infusion 1200 mg/qm q14)
change to 19 cycles cetuximab 
weekly after progress
9.4
29.8
1.2
1.9
nk
Mizota et al. 
[2011]
1 colorectal liver no no mFOLFOX6 + cetuximab 9.7 0.8 nk
Terasawa 
et al. [2013]
1 rectal liver no mFOLOFX6 (80%) after 4 cycles 
escalated to
mFOLFOX6 plus bevacizumab
15.6 0.8 nk
Tural et al. 
[2014]
1 colorectal liver no oxaliplatin, after two weeks 
escalated to FOLFOX6
22.5 1.8 nk
Grenader 
et al. [2009]
1 colon liver, lung no FP/FA (70% of de Gramont regimen) 
escalated to FOLFOX, after 4 weekly 
escalated with bevacizumab
11.2 0.6 nk
Kasi et al. 
[2015]
2 colorectal liver no mFOLFOX7 plus panitumumab 9.4 18.4 1.5
colorectal liver no mFOLFOX7 plus bevacizumab (10 
cycles)
FOLFIRI, followed by FOLFOX plus 
cetuximab
8.4 3.9 18
5-FU, 5-Fluororuracil; nk, not known; red, reduced; LV, leucovorin; Ox, oxaliplatin; OS, overall survival; pts, patients.
Bilirubin levels dropped within 4–8 weeks or nor-
malized within 12 weeks in six patients, (respond-
ers). The remaining six patients showed no 
bilirubin response to systemic treatment (nonre-
sponders). Responders compared with nonre-
sponders were younger (median age of 55.5 years 
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Table 2. Bilirubin levels and individual dosing strategies of systemic treatment with oxaliplatin/ fluoropyrimidine, with or without 
moAbs.
Tumor type 
(mets)
Gender 
(age)
Prior 
Tx
Tx BL Week OS
 1 2 3 4 5 6 7 8 9 10 11 12
1 Rectum 
(liver, bone)
m (66) no Bili 6.7 8.4 – – – 12.5 ϯ ϯ ϯ ϯ ϯ ϯ ϯ 1.3
Ox1 64 – – – – – ϯ ϯ ϯ ϯ ϯ ϯ ϯ
5-FU2 1.5 – – – – – ϯ ϯ ϯ ϯ ϯ ϯ ϯ
2 Colon (liver, 
lung, bone)
m (66) yes Bili 13.3 10.6 6.4 6.4 5.1 3.8 3.8 2.9 2.0 ϯ ϯ ϯ ϯ 2
Ox1 50 50 50 50 50 50 50 50 – ϯ ϯ ϯ ϯ
5-FU2 0 0 0 1.0 1.5 2.0 2.0 2.0 – ϯ ϯ ϯ ϯ
Bev4 5 – 5 – 5 – 5 – – ϯ ϯ ϯ ϯ
3 Colon (liver, 
lymph node)
m (62) yes Bili 11.0 – 10.6 9.3 9.6 7.5 6.9 7.4 6.1 7.6 6.9 – 8.2 5.8
Ox1 65 – 65 – 70 – 70 – 70 – 70 – 85
5-FU2 1,3 – 0 – 1.5 – 1.5 – 1.5 – 1.5 – 1.5
Cet5 – – – – – 400 250 250 250 250 500 – 500
4 Cholangio 
(liver)
m (55) yes Bili 10.8 – – – 7.5 – – – 4.2 – – – 1.4 16
Ox1 50 50 50 – 50 50 50 – 50 50 50 – 50
5-FU2 1.0 1.0 1.0 – 1.0 1.0 1.0 – 1.0 1.0 1.0 – 1.0
5 Gall bladder 
(liver 
peritoneum)
m (56) yes Bili 8.3 – – – 6.8 – 4.4 – 2.3 1.2 1.3 – 1.0 12
Ox1 60 – – – 60 – – – 80 – – – 80
5-FU2 2.4 – – – 2.4 – – – 2.4 – – – 2.4
Tras6 4 – – – 4 – – – 4 – – – 4
6 Colon (liver 
lymph nodes)
f (65) yes Bili 13.6 – 10.1 6.2 4.5 – 2.8 – 1.5 – – 0.8 0.7 14
Ox1 75 – 75 – 75 – 75 – 75 – 75 – 75
5-FU2 1.8 – 1.8 – 1.8 – 1.8 – 1.8 – 1.8 – 1.8
Bev4 5 – 5 – 5 – 5 – 5 – 5 – 5
7 Colon (liver 
lung)
f (73) no Bili 4,0 4.3 3.6 4.3 2,9 2.0 – – 2.6 3.8 6.0 ϯ ϯ 2.5
Ox1 50 50 50 85 – – – – – 50 50 ϯ ϯ
5-FU2 1.5 2.0 2.0 2.0 – – – – – 2.0 2.0 ϯ ϯ
Bev4 – 5 – 5 – – – – – – – ϯ ϯ
8 Colon (liver 
lymph node)
m (49) no Bili 5.5 9.3 11.7 12.2 7.5 4.9 – 4.2 3.3 2.5 – 2.5 2.5 4.5
Ox1 50 50 50 50 – 85 – 85 – 85 – 85 –
5-FU2 1.5 1.5 2.0 2.0 – 2.4 – 2.4 – 2.4 – 2.4 –
Bev4 5 – 5 – – 5 – 5 – 5 – 5 –
9 Cholangio 
(liver lymph 
node)
f (55) yes Bili 2.7 – 2.3 – 3.1 – 4.0 – 4.8 – 2.6 3.5 4.5 10
Ox1 60 – 60 – 85 – 85 – 85 – 85 – 85
5-FU2 1.68 – 1.68 – 2.4 – 2.4 – 2.4 – 2.4 – 2.4
10 Colon (liver, 
lung, lymph 
node)
m (74) yes Bili 3.1 2.3 – – ϯ ϯ ϯ ϯ ϯ ϯ ϯ ϯ ϯ 1
Ox1 50 50 – – ϯ ϯ ϯ ϯ ϯ ϯ ϯ ϯ ϯ
5-FU2 1.5 1.5 – – ϯ ϯ ϯ ϯ ϯ ϯ ϯ ϯ ϯ
11 Cholangio 
(liver, bone)
m (46) yes Bili 2.7 3.3 2.6 – 1.3 – – 1.8 1.8 – – – 1.6 7.5
Ox1 130 – – – 100 – – – 100 – – – 100
Cape3 1.0 1.0 1.0 – 1.0 1.0 1.0 – 1.0 1.0 1.0 – 1.0
12 Esophageal 
(liver, lymph 
node)
m (47) no Bili 3.6 – 1.4 – 0.8 – 0.6 – 0.6 – 0.9 – 0.9 6.5
Ox1 85 – 85 – 85 – 85 – 85 – 85 – 85
5-FU2 1.3 – 1.95 – 1.95 – 2.6 – 2.6 – 2.6 – 2.6
ϯ not application because of death.
Bev, Bevacizumab; Bili, bilirubin in mg/dl (normal value <1.2 mg/dl); BL, baseline; Cape, capecitabine; Cet, Cetuximab; f, female; FP, 5-Fluororuracil; m, male; mets, 
metastases; OS, overall survival; Ox, oxaliplatin; Tras, Trastuzumab ; Tx, treatment.
1 Oxaliplatin was given as weekly FUFOX (oxaliplatin 50 mg/qm), every 2 weeks mFOLFOX6, FOLFOX7 or FLO (oxaliplatin 85 mg/qm) or FOLFOX6 (oxaliplatin 100 mg/qm); 
and every 3 weeks XELOX (oxaliplatin 130 mg/qm).
2 5-FU (5-Fluororuracil) was given as FUFOX (24 h infusion; 2.0 g/qm) weekly; mFOLFOX6 (48 h infusion; 2.4 g/qm) every 2 weeks; FOLFOX7 (48 h infusion; 3.0 g/qm) 
every 2 weeks or FLO (24 h infusion, 2.6 g/qm).
3Capecitabine was given as CAPOX with 1000 mg/qm twice a day for 14 days.
4Bevacizumab, every 2 weeks with 5 mg/kg.
5Cetuximab, loading dose 400 mg/qm, weekly 250 mg/qm, every 2 weeks 500 mg/qm.
6Trastuzumab, 4 mg/kg.
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versus 64 years) and had higher bilirubin levels at 
baseline (9.6 mg/dl versus 4.7 mg/dl).
Median overall survival after start of chemother-
apy was overall 5.75 months (range 1.0–16.0 
months) but was significantly longer in respond-
ers compared with nonresponders [median 9.7 
and 3.0 months, p = 0.026 (two-sided test); 95% 
CI: 1.10–10.22]. Bilirubin level at treatment start 
was not correlated to response rate, side effects or 
survival. Comparing patients with and without 
the combination with moAb, median OS was 6.8 
months and 6.5 months and thus not statistically 
different (p = 0.92).
Apart from severe nausea and emesis (grade 3) in 
one patient the treatment with 5-FU/FA, oxalipl-
atin with or without moAb was well tolerated, even 
after escalation to full dose. No correlation between 
the severity of liver dysfunction, hyperbilirubine-
mia and treatment tolerability was noted.
Discussion
The presented case series clearly demonstrate the 
feasibility of systemic treatment with oxaliplatin/
fluoropyrimidine combinations, with or without 
moAbs. In regard to the low percentage of escala-
tion to a full dose regimen, and the overall rela-
tively poor outcome of these patients, a more 
aggressive dosing strategy and treatment intensity 
should be considered in eligible patients, as out-
come may be correlated to adequate dosage. 
Similarly, recent guidelines (e.g. in mCRC) rec-
ommend an upfront rather intensive treatment 
approach in the case of symptomatic or rapid pro-
gressive disease (ESMO group 2), as commonly 
applies for patients with hyperbilirubinemia 
[Schmoll et  al. 2012]. However, choosing an 
intensive approach with a quick dose escalation 
might not be feasible for all patients and harmful. 
Therefore, a cautious pretreatment evaluation is 
important. In case of an underlying not cancer-
associated reduced ECOG performance status 
(PS) of two or more or a far advanced and already 
heavily pretreated disease, the suggested approach 
may not be reasonable.
Of note, patients without bilirubin response after 
4–8 weeks do not seem to derive any benefit from 
systemic treatment and may thus receive early 
treatment discontinuation and referral to best 
supportive care. In contrast, patients responding 
to treatment as shown by an early decline in bili-
rubin levels may have a longer survival.
The addition of moAbs was feasible, which seems 
to be in line with the known pharmacokinetics in 
these drugs [Lu et al. 2008; Azzopardi et al. 2011; 
Zhi et  al. 2011]. As recently shown, epidermal 
growth factor receptor (EGFR) antibodies seem 
to be of particular interest in terms of application 
as single agent or in combination in RAS wildtype 
mCRC with severe liver dysfunction [Shitara 
et al. 2009; Mizota et al. 2011; Kasi et al. 2015].
The current case series and the respective analy-
ses are limited by the small number of patients, 
the retrospective character and the evaluation of 
patients from only two centers. Therefore, a 
review of literature was performed to collect fur-
ther case series.
Based on the published data and our case series, 
we suggest the following treatment algorithm for 
patients with GI cancer and severe liver dysfunc-
tion (Figure 1).
In case of elevated levels of bilirubin (>2 × 
ULN) due to liver metastases, the option for 
interventional drainage should be evaluated first. 
If bilirubin remains high (or drainage is techni-
cally not possible) and ECOG PS is adequate, 
systemic treatment should be started with a 
dose-reduced regimen, preferably FUFOX 
weekly, with the doses of oxaliplatin 50 mg/qm 
(100%), FA 500 mg/qm (100%) and 5-FU 1500 
mg/qm (75% of the original dosage) for the first 
application [Grothey et al. 2002]. If treatment is 
well tolerated, dosages should also be elevated to 
100 (2000 mg/qm) given for the second applica-
tion. Thereafter, a switch to a biweekly regimen 
with higher single doses (like FOLFOX) is pos-
sible. The combination with moAbs is feasible 
and may thus be considered in eligible patients 
to increase efficacy in this poor prognosis patient 
population.
Conclusion
Liver dysfunction resulting from liver metastases 
in patients with GI malignancies should not lead 
to therapeutic nihilism. In contrary, these 
patients may derive relevant benefit from chemo-
therapy with FA and oxaliplatin with or without 
the addition of a moAbs. Careful upfront patient 
selection based on ECOG PS, comorbidity and 
disease characteristics is important to identify 
patients able to still tolerate such an aggressive 
treatment approach. In regard of the limited data 
further studies are necessary. The recommended 
Therapeutic Advances in Medical Oncology 8(3)
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approach will further be evaluated in a prospec-
tive registry.
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